Please wait while the formulary information is being retrieved.
CANASA (MESALAMINE)
- Ulcerative proctitis
1,000 mg rectal suppository
- Insert 1 suppository (1,000 mg) by rectal route once daily at bedtime
1,000 mg rectal suppository
- Insert 1 suppository (1,000 mg) by rectal route once daily at bedtime
Ulcerative proctitis
- Insert 1 suppository (1,000 mg) by rectal route once daily at bedtime
- Insert 1 suppository (1,000 mg) by rectal route once daily at bedtimefor 3 weeks
- Insert 1 suppository (1,000 mg) by rectal route once daily at bedtimefor 6 weeks
- None
Contraindicated
- Methotrexate (anti-rheumatic)
- methotrexate sodium
- methotrexate sodium (PF)
- Rheumatrex
- Trexall
Severe
Moderate
- acetazolamide
- acetazolamide sodium
- Amaryl
- Arixtra
- colchicine-probenecid
- dalteparin (porcine)
- Diabeta
- Diamox Sequels
- Duetact
- Elmiron
- enoxaparin
- fondaparinux
- Fragmin
- glimepiride
- glipizide
- glipizide-metformin
- Glucotrol
- Glucotrol Xl
- Glucovance
- glyburide
- glyburide micronized
- glyburide-metformin
- Glynase
- heparin (porcine)
- heparin (porcine) in D5W
- heparin(porcine) in 0.45% NaCl
- heparin, porcine (PF)
- Lovenox
- methazolamide
- nateglinide
- Neptazane
- pentosan polysulfate sodium
- pioglitazone-glimepiride
- probenecid
- Starlix
- tolazamide
- tolbutamide
- None
Contraindicated
- Interstitial nephritis
- Minimal change glomerulonephritis
Severe
Moderate
- Anemia
- Disease of liver
- Kidney disease with reduction in GFR
- Neutropenic disorder
CANASA (MESALAMINE)
- Ulcerative proctitis
- Colitis
- Acne vulgaris
- Dizziness
- Fever
- Flatulence
- Headache disorder
- Skin rash
More Frequent
Severe
Less Severe
- None
- Diarrhea
- Flu-like symptoms
- Gastritis
- Nausea
- Rectal pain
Less Frequent
Severe
Less Severe
Rare / Very Rare
Severe
- Abdominal pain with cramps
- Abnormal hepatic function tests
- Acute pancreatitis
- Agranulocytosis
- Alveolitis
- Aplastic anemia
- Bloody diarrhea
- Drug fever
- Eosinophilia
- Erythema nodosum
- Gastrointestinal hemorrhage
- Guillain-barre syndrome
- Hepatic failure
- Hepatic necrosis
- Hepatitis
- Hypersensitivity drug reaction
- Hypersensitivity pneumonitis
- Intracranial hypertension
- Jaundice
- Lupus-like syndrome
- Myelitis
- Myocarditis
- Nephrogenic diabetes insipidus
- Nephrotoxicity
- Neutropenic disorder
- Obstructive hyperbilirubinemia
- Pericarditis
- Pyoderma gangrenosum
- Rectal irritation
- Severe headache disorder
- Thrombocytopenic disorder
Less Severe
- Alopecia
- Back pain
- Constipation
- Discolored feces
- Erythema
- Female infertility
- Hemorrhoids
- Limb pain
- Oligospermia
- Periorbital edema
- Peripheral neuropathy
- Pruritus ani
- Pruritus of skin
- Psoriasis
- Tenesmus
- Urticaria
Contraindicated
None
Severe Precaution
None
Management or Monitoring Precaution
Mesalamine
Safety and efficacy not established age < 5 years.
No demonstrated efficacy for ulcerative proctitis.
- 1 Day – 5 Years
- Safety and efficacy not established age < 5 years.
- 5 Years – 18 Years
- Safety and efficacy not established age < 5 years.
Mesalamine (rectal_supp)
Safety and efficacy not established age < 5 years.
No demonstrated efficacy for ulcerative proctitis.
- 1 Day – 5 Years
- No demonstrated efficacy for ulcerative proctitis.
- 5 Years – 18 Years
- No demonstrated efficacy for ulcerative proctitis.
Mesalamine (5 Aminosalicylic Acid)
- Severity Level:
2
- Additional Notes: Insufficient human data; animal data do not suggest fetal risk
Contraindicated
None
| General | Excretion Potential | Effect on Infant | Notes |
| None |
Precaution Exists
Mesalamine (5-aminosalicylic Acid)
Metabolite excreted in high levels w/unknwn infant risk;Few cases of diarrhea
| General | Excretion Potential | Effect on Infant | Notes |
| Evaluate use carefully | Excreted | Drug shown to have adverse effect | Metabolite excreted in high levels w/unknwn infant risk;Few cases of diarrhea |
No Known Risk
None
| General | Excretion Potential | Effect on Infant | Notes |
| None |
Contraindicated
None
Precaution Exists
Mesalamine
Renal-Monitor renal function as elderly are more sensitive to renal toxicity. Higher AUC and decreased elimination observed. Hematologic-Increased risk of neutropenia or pancytopenia. Monitor complete blood cell counts and platelet counts in elderly patients during treatment.
| Organ / System | HEP | REN | CARD | ENDO | NEURO / PSYCH | PULM |
| Increased Risk / Adverse Effects | Y | N | N | N | N | N |
BEERS: N HEDIS: N STOPP: N
No Known Risk
None
- None
| Ulcerative proctitis | |
| K51.2 | Ulcerative (chronic) proctitis |
| K51.20 | Ulcerative (chronic) proctitis without complications |
| K51.21 | Ulcerative (chronic) proctitis with complications |
| K51.211 | Ulcerative (chronic) proctitis with rectal bleeding |
| K51.212 | Ulcerative (chronic) proctitis with intestinal obstruction |
| K51.213 | Ulcerative (chronic) proctitis with fistula |
| K51.214 | Ulcerative (chronic) proctitis with abscess |
| K51.218 | Ulcerative (chronic) proctitis with other complication |
| K51.219 | Ulcerative (chronic) proctitis with unspecified complications |
| 0-9 | A-Z |
|---|---|
| K51.2 | Ulcerative (chronic) proctitis |
| K51.20 | Ulcerative (chronic) proctitis without complications |
| K51.21 | Ulcerative (chronic) proctitis with complications |
| K51.211 | Ulcerative (chronic) proctitis with rectal bleeding |
| K51.212 | Ulcerative (chronic) proctitis with intestinal obstruction |
| K51.213 | Ulcerative (chronic) proctitis with fistula |
| K51.214 | Ulcerative (chronic) proctitis with abscess |
| K51.218 | Ulcerative (chronic) proctitis with other complication |
| K51.219 | Ulcerative (chronic) proctitis with unspecified complications |
Formulary Reference Tool